Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

1.2K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
1.1K
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

956
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
956
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.6K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.6K
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

1.0K
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
1.0K
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

1.1K
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Better outcomes for the older surgical patient trial (BOOST): protocol for a hybrid type 1 effectiveness-implementation trial of an embedded geriatric perioperative service within emergency and elective surgery in an Australian tertiary referral hospital.

BMJ open·2026
Same author

An Australian Co-Designed Template for Accessible Medicines Information for People With Intellectual Disability.

Journal of applied research in intellectual disabilities : JARID·2026
Same author

Evaluating Australia's "MyMedicare" voluntary patient registration system: the prospective evaluation of patient registration study protocol.

Frontiers in health services·2026
Same author

Epidemiology, Microbiology, Management and Outcomes of Endophthalmitis: An 18 Year Retrospective Observational Study at a Tertiary Referral Center in Australia.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Effects of Obesity on Minimally Invasive Lumbar Spine Surgery: A Systematic Review and Meta-Analysis.

International journal of spine surgery·2026
Same author

Vocal Cord Dysfunction / Inducible Laryngeal Obstruction (VCD/ILO) as a Mimic of Anaphylaxis: A Retrospective Cohort Study.

The journal of allergy and clinical immunology. In practice·2026

Related Experiment Video

Updated: Apr 19, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.2K

Cannabis and schizophrenia.

Jonathan A Pushpa-Rajah1, Benjamin C McLoughlin2, Donna Gillies3

  • 1Queens Medical Centre, School of Medicine, The University of Nottingham, Nottinghamshire, UK; Pushpa-Rajah and Benjamin Mcloughin were co-lead authors. mzyjp3@nottingham.ac.uk.

Schizophrenia Bulletin
|January 2, 2015
PubMed
Summary
This summary is machine-generated.

Limited research on cannabis use in schizophrenia shows no clear benefits or harms from psychological or drug therapies for reduction. More high-quality trials are needed to understand cannabis effects and treatment efficacy.

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

952

Related Experiment Videos

Last Updated: Apr 19, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.2K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

952

Area of Science:

  • Psychiatry and Mental Health
  • Addiction Medicine
  • Pharmacology

Background:

  • A significant number of individuals with schizophrenia use cannabis, with unclear reasons and health implications.
  • Optimal strategies for managing cannabis intake in this population remain undefined.

Purpose of the Study:

  • To evaluate psychological treatments for reducing cannabis use in schizophrenia patients.
  • To assess the efficacy of antipsychotic medications in decreasing cannabis consumption.
  • To investigate the impact of cannabinoids on symptom reduction in schizophrenia.

Main Methods:

  • Comprehensive search of the Cochrane Schizophrenia Group Trials Register and relevant trial references.
  • Inclusion of all randomized controlled trials (RCTs) examining cannabinoids and schizophrenia.
  • Assessment of trials focusing on cannabis reduction treatments and cannabinoid effects on schizophrenia symptoms.

Main Results:

  • The available RCTs are few, small, and report data of limited quality, leading to inconclusive findings.
  • No specific adjunct psychological therapy or drug therapy has demonstrated superior effectiveness for cannabis reduction.
  • Insufficient evidence exists to support cannabidiol as an effective antipsychotic treatment.

Conclusions:

  • Current evidence is insufficient to guide clinical practice regarding cannabis reduction or cannabinoid use in schizophrenia.
  • Further high-quality randomized controlled trials are necessary to clarify the effects of cannabis and potential treatments.